1. Introduction {#sec0005}
===============

The porcine epidemic diarrhea virus (PEDV) is an enveloped, single-stranded positive-sense RNA virus that causes porcine epidemic diarrhea (PED), an acute and highly contagious enteric disease in pigs. PED is characterized by severe diarrhea, vomiting, dehydration, and a mortality rate of up to 90% in suckling piglets ([@bib0185]). PED was first reported in Belgium and the United Kingdom in 1978, and frequent outbreaks have occurred in various Asian countries ([@bib0025]). Since 2007, acute PED outbreaks have continually occurred in Thailand, China, and the USA, which have resulted in substantial economic losses ([@bib0190], [@bib0120], [@bib0020], [@bib0100], [@bib0135], [@bib0220], [@bib0275], [@bib0030]). The continued outbreaks of PED, despite control efforts, have caused widespread concern.

The PEDV belongs to the genus *Alphacoronavirus*, in the family *Coronaviridae* and order *Nidovirales* ([@bib0010]). Previous studies have investigated various control measures to protect against PEDV infection, such as vaccines, diagnostic tools, and therapeutic drugs ([@bib0245], [@bib0200], [@bib0235], [@bib0305], [@bib0060], [@bib0110]). Various aspects of PEDV infection remain unclear, for example, swine testis (ST) cells expressing porcine aminopeptidase N of PEDV receptor were not susceptible to PEDV infection. African green monkey kidney (Vero) cells are highly susceptible to PEDV infection, and are widely used for the primary isolation and cultivation of PEDV ([@bib0165], [@bib0065]). Therefore, Vero lineages are suitable hosts for understanding the mechanisms of PEDV infection.

Proteomics techniques are effective tools for characterizing protein expression profiles, and have been used widely to investigate disease-associated proteins ([@bib0095], [@bib0015], [@bib0070], [@bib0240]). Among current proteomics methods, quantitative high-throughput proteomics approaches are useful for the analysis of infection-associated proteins of pathogens ([@bib0125], [@bib0170], [@bib0280], [@bib0295]). In our current study, we used a quantitative proteomics approach based on an iTRAQ tandem mass spectrometry (MS/MS) technique to identify proteins differentially expressed between PEDV-infected and mock-infected Vero E6 cells. The functions of the differentially expressed proteins (DEPs) were analyzed to determine whether they might be associated with PEDV infection. Our findings provide valuable insight into the changes in cellular processes that occur during PEDV infection.

2. Materials and methods {#sec0010}
========================

2.1. Virus, cells, and antibody {#sec0015}
-------------------------------

The CV777 strain of PEDV, kindly provided by Maurice Pensaert at Ghent University (Merelbeke, Belgium), was used in all of our experiments after being adapted to Vero E6 cells, as previously described ([@bib0090]). The Vero E6 cell-adapted PEDV, the Vero E6 cells, and the monoclonal antibody against the nucleocapsid protein (Np) of PEDV were stored at the Diarrhea-Related Viruses Section, Division of Swine Infectious Diseases, National Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences.

2.2. Viral infection of Vero E6 cells {#sec0020}
-------------------------------------

The Vero E6 cells were cultured in Dulbecco\'s modified Eagle\'s medium containing 10% fetal bovine serum (FBS) in 75-cm flasks at 37 °C in a 5% CO~2~ atmosphere. When the cells reached 70--80% confluence, they were inoculated with the PEDV at a multiplicity of infection of 1 in presence of 5 μg/mL trypsin. At 48 h postinoculation, the cells began to exhibit cytopathic effects (CPEs) of viral infection, but no cells lysis or shedding had occurred. The cells were washed three times with cold phosphate-buffered saline (PBS, pH 7.4). A 1.5-mL aliquot of lysis buffer containing 4% SDS, 1 mM DTT, and 150 mM Tris--HCl (pH 8.0) was added to each flask, and the flasks were incubated at 37 °C for 5 min. The cell lysates were collected using a cell scraper, and boiled for 5 min. Three cell lysate replicates were prepared for the PEDV-infected (V1--V3) and mock-infected (C1--C3) Vero E6 cells, and stored at −80 °C.

2.3. Immunoblotting {#sec0025}
-------------------

Western blotting was performed to confirm PEDV infection by detecting the presence of the Np of PEDV in the Vero E6 cells. Aliquots of the cell lysates were subjected to SDS-PAGE on a 12% acrylamide gel, and the protein bands were transferred to a nitrocellulose membrane using a semi-dry transfer device (Bio-Rad, Hercules, CA, USA). The membrane was blocked using 5% (w/v) nonfat dried milk in PBS at 37 °C for 1 h, before incubation in PBS containing the anti-Np monoclonal antibody (1:2000 dilution) at 37 °C for 1 h. After washing three times with 5% Tween 20 in PBS (PBST), the membrane was incubated in PBST containing a horseradish peroxidase-conjugated goat anti-mouse IgG (1:4000 dilution) at 37 °C for 1 h. After washing three times with PBS, the membrane was incubated with enhanced chemiluminescence detection reagents (Biotopped, Beijing, China) at room temperature for 3 min, and the peroxidase-mediated luminescence was digitally captured using the Molecular Imager ChemiDoc XRS+ System (Bio-Rad) and the Image Lab software (Bio-Rad). To verify the differential expression of the selected DEPs, equivalent volumes of the cell lysate replicates from the PEDV-infected (V1--V3) and mock-infected (C1--C3) Vero E6 cells were pooled into the V and C samples, respectively, and western blotting was performed as described above, with the following exceptions: a 1:1000 dilution of the polyclonal antibodies anti-β tubulin, anti-integrin-β3, anti-cystatin-C, anti-protein S100-A2, anti-apolipoprotein E4, and anti-centrin from rabbit (Beijing Biosynthesis Biotechnology, Beijing, China) was used as the primary antibody, and a 1:5000 dilution of the HRP-conjugated goat anti-rabbit IgG (Sigma--Aldrich, St. Louis, USA) was used as the secondary antibody.

2.4. Protein digestion and iTRAQ labeling {#sec0030}
-----------------------------------------

Protein digestion of the samples was performed according to the FASP procedure described by [@bib0270]. An aliquot of each cell lysate containing 200 μg of protein was combined with 30 μL of STD buffer containing 4% SDS, 100 mM DTT, and 150 mM Tris--HCl (pH 8.0). The detergent, DTT, and other low-molecular-weight components were removed by dilution in UA buffer containing 8 M Urea and 150 mM Tris--HCl (pH 8.0) and repeated ultrafiltration using Microcon (30 kDa) ultrafiltration units. The reduction of cysteine residues was blocked by the addition of 100 μL of 0.05 M iodoacetamide to the UA buffer. The samples were incubated for 20 min in darkness before ultrafiltration. The Microcon filters were washed three times with 100 μL of UA buffer, followed by two washes with 100 μL DS buffer containing 50 mM triethyl ammonium bicarbonate (pH 8.5). The final protein suspensions were digested using 2 μg of trypsin (Promega, Madison, WI, USA) in 40 μL of DS buffer overnight at 37 °C, and the digested peptides were collected as the filtrate. The peptide content was quantified based on absorbance at 280 nm using an extinction coefficient of 1.1 for a 0.1 mg/mL solution. The digested peptide mixture was labeled using the 8-plex iTRAQ reagent (Life Technologies, Carlsbad, CA, USA), according to the manufacturer\'s instructions. Each iTRAQ reagent was dissolved in 70 μL of ethanol, and added to the digested peptide mixture. The samples were labeled as C1-113, C2-114, C3-115, V1-116, V2-117, or V3-118. The samples were multiplexed, and vacuum dried.

2.5. Peptide fractionation with strong cation exchange chromatography (SCXC) {#sec0035}
----------------------------------------------------------------------------

The iTRAQ labeled peptides were fractionated by SCXC using the AKTA Purifier system (GE Healthcare, Waukesha, WI, USA). The dried peptide mixture was reconstituted, and acidified by the addition of 2 mL of buffer A containing 10 mM KH~2~PO~4~ in 25% acetonitrile (pH 2.7). The samples were loaded onto a 4.6 mm × 100 mm column packed with Polysulfoethyl (5 μm, 200 Å) chromatography resin (PolyLC, Columbia, Maryland, USA). The peptides were eluted at a flow rate of 1 mL/min using a gradient of 0--10% buffer B containing 500 mM KCl and 10 mM KH~2~PO~4~ in 25% acetonitrile (pH 2.7). The gradient elution consisted of 10--20% buffer B for 25 min, 20--45% buffer B for 5 min, and 50--100% buffer B for 5 min. The absorbance of the eluate was monitored at 214 nm, and fractions were collected at 1-min intervals. Thirty fractions were combined into ten pools, and desalted using Empore standard density SPE C18 cartridges (Sigma--Aldrich, St. Louis, MO, USA) with a bed diameter of 7 mm and a volume 3 mL. Each fraction was concentrated by centrifugation in a vacuum, and reconstituted in 40 μL of 0.1% (v/v) trifluoroacetic acid. All samples were stored at −80 °C until the MS analysis was performed.

2.6. Liquid chromatography (LC) MS/MS analysis {#sec0040}
----------------------------------------------

The LC--MS/MS experiments were performed using a Q Exactive mass spectrometer coupled to a Proxeon Biosystem Easy nanoLC (Thermo Fisher Scientific, Waltham, MA, USA). Ten microliters of each fraction was injected for nanoLC--MS/MS analysis. The peptide mixture (5 μg) was loaded onto a C18-reversed phase column (15 cm × 75 μm) packed with RP-C18 (5 μm) resin in buffer A containing 0.1% formic acid, and eluted with a linear gradient of buffer B (80% acetonitrile and 0.1% formic acid) at a flow rate of 0.25 μL/min for 140 min using the IntelliFlow technology. The eluate underwent electrospray ionization for the MS/MS analysis. The MS/MS instrument was run in the peptide recognition mode, and the spectra were acquired using a data-dependent top-10 method based on the selection of the most abundant precursor ions from the survey scan (300--1800 *m*/*z*) for HCD fragmentation. The determination of the target value was based on the predictive automatic gain control, and the dynamic exclusion duration was 60 s. Survey scans were acquired at a resolution of 70, 000 at *m*/*z* 200, and the resolution for the HCD spectra was set to 17, 500 at *m*/*z* 200. The normalized collision energy was 30 eV, and the underfill ratio, which specifies the minimum percentage of the target value likely to be reached at maximum fill time, was defined as 0.1%.

2.7. Identification and analysis of proteins {#sec0045}
--------------------------------------------

The MS/MS spectra were compared to the Uniprot *Cercopithecidae* database (107 051 sequences, downloaded November 25, 2013) and a decoy database using the MASCOT search engine, version 2.2 (Matrix Science, London, UK), embedded in the Proteome Discoverer 1.4 software (Thermo Electron, San Jose, CA). The following parameters were used for protein identification: a peptide mass tolerance of 20 ppm; an MS/MS tolerance of 0.1 Da; trypsin digestion; a missed cleavage value of 2; the fixed modifications included carbamidomethyl, iTRAQ8plex(K), and iTRAQ8plex(N-term); the variable modification was oxidation; and an FDR value ≤0.01. Protein quantification was performed using the Proteome Discoverer 1.4 software based on the centroided reporter ion peak intensity. The average quantitative value of each protein in samples C1, C2, and C3 (mock-infection group) was used as the internal reference. The value of the quantitative ratio for each protein relative to the internal reference was calculated, and averaged to obtain the quantitative ratio (*V*/*C*) of the proteins identified in the treatment groups ([@bib0255]). A protein was considered to be differentially expressed between the PEDV-infected and mock-infected groups based on the following criteria: the protein had to be present in three replicates of both groups, the difference in the level of the protein between the two groups had to be statistically significant (*P*  \< 0.05), and the change ratio for the protein had to be ≥1.2 ([@bib0290]). The expression of a protein with a *V*/*C*  \> 1.0 was considered to be up-regulated, and those with a *V*/*C*  \< 1.0 were considered to be down-regulated. The data were analyzed using a two-tailed, paired Student\'s *t* test. The statistical analysis was performed using the Excel 2007 software (Microsoft, Redmond, WA, USA). The DEPs were annotated using the Blast2GO, version 2.7.0, program ([@bib0005], [@bib0195], [@bib0050]). The DEPs were blasted against the KEGG Genes database (human). The Gene Ontology categories (GOCs) were retrieved, and mapped to pathways in the KEGG database ([@bib0105]).

3. Results {#sec0050}
==========

3.1. Identification and analysis of proteins {#sec0055}
--------------------------------------------

The Vero E6 cells inoculated with PEDV displayed distinct CPEs at 48 h postinoculation, including cell shrinkage, cell fusion, and a rounded cell morphology, but no cells lysis or shedding was observed ([Fig. 1](#fig0005){ref-type="fig"}A). The immunoblotting analysis confirmed that the Vero E6 cells were PEDV-infected. The band corresponding to the Np of PEDV was detected in samples V1, V2, and V3, whereas none was detected in samples C1, C2, and C3 ([Fig. 1](#fig0005){ref-type="fig"}B). The identified peptides, identified proteins, quantified proteins, known/uncharacterized proteins, and the GOC annotations are showed in [Table 1](#tbl0005){ref-type="table"} . A total of 3178 proteins, including 15 564 peptides, were identified in the PEDV-infected and mock-infected groups using the iTRAQ-MS/MS approach, among which 3171 (99.78%) were quantified, 1859 (58.50%) were known proteins, and 1319 (41.50%) were uncharacterized/putative proteins. Based on the GOCs, 2061 (64.85%) of the proteins were annotated as biological process, 2495 (78.51%) were annotated as molecular function, and 1917 (60.32%) were annotated as cellular components.Fig. 1Preparation and identification of PEDV-infected Vero E6 cells. (A) Photomicrographs of PEDV-infected Vero E6 cells or mock-infected Vero E6 cells: C, mock-infected group; V, PEDV-infected group. (B) Verification of PEDV propagation in Vero E6 cells by western blot: C, mock-infected group; V, PEDV-infected group.Table 1The proteins identified from PEDV-infected and mock-infected groups.ClassificationNumber of proteins (percentage)Identified peptides15,564Identified proteins3178 (100%)Quantified proteins3171 (99.78%)Known proteins1859 (58.50%)Uncharacterized proteins1319 (41.50%)Annotated proteins in GO categories of biological process2061 (64.85%)Annotated proteins in GO categories of molecular function2495 (78.51%)Annotated proteins in GO categories of cellular component1917 (60.32%)

The quantification and significance of the identified proteins are shown in [Fig. 2](#fig0010){ref-type="fig"} . The changes in the levels of expression between the two groups were analyzed based on statistical significance. Of the 3178 proteins identified, 2496 (78.54%) were not differentially expressed (*P*  \> 0.05), and 675 (21.24%) were expressed at statistically different levels between the PEDV-infected and mock-infected Vero E6 cells (*P *\< 0.05), including 357 proteins (11.23%) with a *P*-value between 0.01 and 0.05, 227 proteins (7.14%) with a *P*-value between 0.001 and 0.01, and 91 proteins (2.86%) with a *P*-value \<0.001. The proteins with a *P*-value \<0.05 were also filtered based on whether the *V*/*C* or *C*/*V* was ≥1.2. Based on these criteria, a total of 126 (3.96%) of the 3178 identified proteins were determined to have been differentially expressed between the PEDV-infected and mock-infected groups ([Table 2](#tbl0010){ref-type="table"} ). Among the 126 DEPs, 46.03% (58/126) were up-regulated, and 53.97% (68/126) down-regulated. The known proteins and uncharacterized/putative proteins accounted for 69.05% (87/126) and 30.95% (39/126) of the DEPs, respectively. The DEP displaying the greatest increase in expression in the PEDV-infected Vero E6 cells was isoform 2 of the ovarian cancer immunoreactive antigen domain-containing 1 protein (1:2.5), and the DEP displaying the greatest decrease in expression in the PEDV-infected Vero E6 cells was cystatin-C (1:2.2).Fig. 2The quantitation and significance of the 3178 identified proteins from PEDV-infected and mock-infected groups.Table 2The differentially expressed protein lists between PEDV-infected and mock-infected groups.No.Protein nameUniProtKB accession no.GO annotation*P* valueAverage *V*/*C*[b](#tblfn0010){ref-type="table-fn"}Molecular functionCellular componentBiological process1Cystatin-C or Cystatin-3G7PH52enzyme regulator activity--metabolic process; regulation of biological process6.98E−040.462[a](#tblfn0005){ref-type="table-fn"}Osteopontin precursorF7F5L5------9.11E−030.503Retinol dehydrogenase 10G7MZK0nucleotide binding; catalytic activitycytoplasm; membranedevelopment; metabolic process; reproduction; cell differentiation5.22E−030.594Testis cDNA cloneQ4R3Z6------1.36E−030.595Overexpressed in colon carcinoma 1 proteinH9FAZ7------6.48E−040.616Cytochrome b-245 light chainH9F3U1--membrane--1.11E−020.627[a](#tblfn0005){ref-type="table-fn"}Centrin-2F7HKU5metal ion binding; nucleotide binding; catalytic activity----1.26E−030.668[a](#tblfn0005){ref-type="table-fn"}Kidney-specific cadherinF6VCT3metal ion bindingmembrane--6.70E−050.679[a](#tblfn0005){ref-type="table-fn"}Putative WD repeat-containing protein 33F6SBK9protein bindingnucleus--1.36E−030.6710Apolipoprotein E4D5G333--extracellulartransport; metabolic process9.85E−030.6811Receptor-type tyrosine-protein phosphatase T isoform 1H9F9X9catalytic activitymembranemetabolic process3.56E−030.6812[a](#tblfn0005){ref-type="table-fn"}Putative neutral and basic amino acid transport protein rBAT-like isoform 3F7HIT7catalytic activity--metabolic process8.18E−050.6913[a](#tblfn0005){ref-type="table-fn"}Mitochondrial ornithine aminotransferaseF7BGF3catalytic activitycytoplasm; mitochondrionmetabolic process; cell organization and biogenesis3.51E−020.6914Lysosomal protective proteinG7N4N3catalytic activitynucleusmetabolic process2.85E-050.7015[a](#tblfn0005){ref-type="table-fn"}Putative low-density lipoprotein receptor-related protein 2F7H113metal ion binding; protein bindingcytoplasm; endosome; endoplasmic reticulum; Golgi; membranemetabolic process; transport; cell proliferation; development1.02E−040.7016Alpha-adducin isoform cH9FPQ1metal ion bindingcytoskeleton--3.58E−030.7117Integrin beta 2H9Z8N5receptor activity; protein bindingmembranecell communication; regulation of biological process; response to stimulus; development1.82E−040.7118Dipeptidyl peptidase 2 preproproteinH9EXB4catalytic activitymembranemetabolic process4.22E−030.7119[a](#tblfn0005){ref-type="table-fn"}Estrogen sulfotransferaseF6RUQ2catalytic activitynucleus; cytoplasm; membranemetabolic process4.73E−030.7120[a](#tblfn0005){ref-type="table-fn"}Putative protein EGK_14077F6PJM4------2.34E−030.7221[a](#tblfn0005){ref-type="table-fn"}Putative legumainF6S082catalytic activitycytoplasm; endosomeresponse to stimulus; metabolic process; regulation of biological process; cell death2.53E−030.7322Metallothionein-1EF6PYY1metal ion bindingnucleus; cytoplasmregulation of biological process; response to stimulus4.86E−030.7423Trophoblast glycoproteinH9F4Q1protein bindingmembrane--6.68E−040.7424[a](#tblfn0005){ref-type="table-fn"}Putative proactivator polypeptide isoform X6F7F376--cytoplasm; vacuolemetabolic process6.40E−030.7425Cathepsin D (Predicted)A9L947catalytic activity--metabolic process1.33E−040.7526Aldehyde dehydrogenase family 1 member L1F7HB04catalytic activitycytoplasm; mitochondrionmetabolic process9.07E−030.7527Carbonic anhydrase 2G7MZP3catalytic activity; metal ion binding--metabolic process1.83E−030.7528Erythrocyte band 7 integral membrane protein isoform aF7HP19--cytoskeleton; membrane; extracellularcell organization and biogenesis4.40E−050.7529[a](#tblfn0005){ref-type="table-fn"}Putative laminin subunit beta-1F7HPY4catalytic activity; motor activity; signal transducer activity; protein binding; structural molecule activity; nucleotide bindingextracellular; nucleus; cytoplasm; membrane; cytoskeleton; mitochondrionmetabolic process; regulation of biological process; cell communication; response to stimulus; transport; cellular component movement; development; cell differentiation; cell organization and biogenesis1.92E−030.7630[a](#tblfn0005){ref-type="table-fn"}Putative tissue alpha-L-fucosidaseF7HDC0catalytic activity--metabolic process6.56E−030.7631Similar to human bone marrow stromal cell antigen 1I7GP78catalytic activity----2.77E−020.7732Solute carrier family 17, member 5A9X190--membranetransport8.00E−030.7733GalectinG7N3S9------2.88E−030.7834Sulfhydryl oxidase 2H9F332catalytic activitymembranemetabolic process4.97E−030.7835Folate receptor alphaF7BP60------2.98E−030.7836[a](#tblfn0005){ref-type="table-fn"}Putative protein EGK_10171G7NLB0------4.60E−030.7937Lysosome-associated membrane glycoprotein 2 isoform BF7BCK9--membrane--1.61E−030.7938RNA-binding motif protein 12BG7MZR8nucleotide bindingmembrane--2.10E−030.7939Similar to human synaptobrevin-like 1 (SYBL1)I7G8H0--membranetransport8.83E−030.7940[a](#tblfn0005){ref-type="table-fn"}Putative polyadenylate-binding protein-interacting protein 1 isoform 2F7H0R0DNA binding; RNA binding; protein binding--metabolic process1.17E−040.7941[a](#tblfn0005){ref-type="table-fn"}Putative versican core protein-like isoform 8F7C5T5metal ion binding; protein bindingextracellularcell differentiation; cellular component movement; development5.67E−050.7942[a](#tblfn0005){ref-type="table-fn"}Putative N-acetylglucosamine-6-sulfataseG7PIY5catalytic activitycytoplasm; vacuolemetabolic process1.14E−040.8043ACADSBQ5IFK6catalytic activity; nucleotide binding--metabolic process3.47E−020.8044ClusterinQ5ISQ2--cell death2.54E−030.8045Cathepsin ZG7N4B3catalytic activity--metabolic process6.96E−030.8046[a](#tblfn0005){ref-type="table-fn"}Endoplasmic reticulum resident protein 28F7GNV5--cytoplasm; endoplasmic reticulum; organelle lumentransport4.49E−020.8047[a](#tblfn0005){ref-type="table-fn"}Putative transducin-like enhancer protein 4 isoform 12F6PZC8protein bindingnucleusmetabolic process; regulation of biological process2.22E−030.8148[a](#tblfn0005){ref-type="table-fn"}T-cell immunoglobulin and mucin domain-containing protein 1F7GB98protein binding----4.71E−050.8149[a](#tblfn0005){ref-type="table-fn"}Putative N-acetylgalactosamine-6-sulfataseG7NQ90catalytic activity--metabolic process1.58E−020.8150[a](#tblfn0005){ref-type="table-fn"}Uncharacterized proteinF7GQ07catalytic activity--metabolic process3.01E−040.8151[a](#tblfn0005){ref-type="table-fn"}Putative galactokinaseF7DF76nucleotide binding; catalytic activitycytoplasmmetabolic process4.72E−020.8152Signal transducer and activator of transcriptionQ9N145protein binding; DNA binding; signal transducer activitynucleus; cytoplasm; membranecell differentiation; development; metabolic process; regulation of biological process; transport; cell communication; response to stimulus; cell proliferation; reproduction7.92E−030.8153Delta(14)-sterol reductaseG7PPJ4catalytic activitymembranemetabolic process3.51E−020.8154[a](#tblfn0005){ref-type="table-fn"}Putative disabled homolog 2 isoform X4F7GRX9protein binding----4.59E−030.8155Pyridoxal-dependent decarboxylase domain-containing protein 1F7GW28catalytic activity--metabolic process1.59E−020.8156Rho GTPase-activating protein 29H9FI14metal ion bindingmembranecell communication; regulation of biological process; response to stimulus1.51E−020.8257Protein DB83F7H2H1--membrane; cytoplasm--2.25E−030.8258DORA reverse strand proteinG7Q0P8catalytic activity--metabolic process1.01E−020.8259Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (Cyclizing)G7PPY4catalytic activity; nucleotide bindingmembranemetabolic process4.96E−030.8260Cadherin 6Q5ISM2metal ion bindingmembrane--6.61E−030.8261[a](#tblfn0005){ref-type="table-fn"}Putative mitochondrial delta(3,5)-Delta(2,4)-dienoyl-CoA isomeraseF6TNT1catalytic activity; protein bindingcytoplasm; mitochondrionmetabolic process5.83E−030.8262Fatty acid-binding protein, heartG7MI71transporter activity--transport2.36E−030.8263[a](#tblfn0005){ref-type="table-fn"}Putative NADH dehydrogenase 1 α subcomplex subunit 8F7B3T9--cytoplasm; mitochondrion; membrane--1.78E−030.8364Endoplasmic reticulum resident protein 58G7NJK7protein bindingcytoplasm; endoplasmic reticulum; organelle lumen--5.49E−030.8365AgrinH9FU64transporter activity; protein bindingextracellular; membranetransport; cell communication; regulation of biological process; response to stimulus; cell organization and biogenesis9.20E−030.8366[a](#tblfn0005){ref-type="table-fn"}Toll-interacting proteinF7DRQ6protein binding----2.53E−020.8367[a](#tblfn0005){ref-type="table-fn"}Putative tetraspanin-3 isoform X2F6SRI3--membrane--3.37E−030.8368[a](#tblfn0005){ref-type="table-fn"}Putative protein EGK_14027G7MM35enzyme regulator activity; protein bindingcytoplasm; cytoskeleton; membranemetabolic process; regulation of biological process6.05E−030.8369Inosine-5′-monophosphate dehydrogenaseF6VXT4nucleotide binding; catalytic activity; protein binding; metal ion bindingnucleus; cytoplasm; membranemetabolic process; cell proliferation; response to stimulus3.12E−041.207078 kDa glucose-regulated proteinF7C3R1nucleotide binding; catalytic activity; protein bindingnucleus; cytoplasm; endoplasmic reticulum; cell surface; membranecell organization and biogenesis; cell communication; regulation of biological process; response to stimulus; metabolic process; development; cell death9.49E−051.2071[a](#tblfn0005){ref-type="table-fn"}Uncharacterized proteinF6W6U2------1.40E−021.2072[a](#tblfn0005){ref-type="table-fn"}Follistatin-related protein 1G7MKF2metal ion binding; protein binding----3.29E−041.2073[a](#tblfn0005){ref-type="table-fn"}Putative retrotransposon-like protein 1F7G2J3RNA binding; catalytic activity--metabolic process6.78E−041.2074[a](#tblfn0005){ref-type="table-fn"}Heat shock protein 105 kDaF6S529nucleotide binding----6.60E−051.2175[a](#tblfn0005){ref-type="table-fn"}Putative protein midA homologF7GTQ7------2.96E−031.2176Similar to human S-adenosylhomocysteine hydrolase-like 1I7GBN2catalytic activity--metabolic process; transport9.34E−031.2177Transferrin receptor 1F6UX47catalytic activityextracellular; cytoplasm; endosome; membrane; cell surfacemetabolic process; cellular homeostasis; cell differentiation; development; regulation of biological process4.64E−041.2278[a](#tblfn0005){ref-type="table-fn"}Exocyst complex component 6BF7GZR4--cytoplasmtransport5.75E−031.2279Protein S100-A2H9F670metal ion bindingmembrane--4.75E−021.2280[a](#tblfn0005){ref-type="table-fn"}Ephrin type-A receptor 2F7E018nucleotide binding; catalytic activity; receptor activity; signal transducer activity; protein bindingmembranedevelopment; cell differentiation; metabolic process; cell communication; regulation of biological process; response to stimulus; cell death; cell organization and biogenesis; cell proliferation; cellular component movement3.02E−021.2281[a](#tblfn0005){ref-type="table-fn"}Putative nucleolar RNA helicase 2-like isoform 3F6SQP8nucleotide binding; RNA binding; catalytic activitynucleus--1.12E−031.2382[a](#tblfn0005){ref-type="table-fn"}Putative polyadenylate-binding protein 1-like isoform X2F7EU27nucleotide binding; RNA binding----1.77E−031.2383[a](#tblfn0005){ref-type="table-fn"}Uncharacterized proteinF7CEU8nucleotide binding----5.52E−031.2384Sequestosome-1 isoform 1I2CY26metal ion binding----8.51E−031.2385NEDD8 ultimate buster 1 isoform 2H9EZG1protein binding--metabolic process; regulation of biological process; defense response; response to stimulus2.32E−021.2386Thioredoxin domain-containing protein 9F6YEB0--nucleus; cytoplasm; cytoskeletoncellular homeostasis; regulation of biological process3.79E−021.2387Four and a half LIM domains protein 2F7GXH4protein binding; metal ion bindingnucleus; cytoskeletonmetabolic process; regulation of biological process; cell differentiation; response to stimulus; cell death; development2.24E−051.2388Similar to human DKFZP564M182 proteinI7G2J1RNA binding; structural molecule activitycytoplasm; ribosomemetabolic process2.95E−031.2389Similar to human hypothetical protein FLJ10634I7GMW8nucleotide binding----1.69E−021.2390[a](#tblfn0005){ref-type="table-fn"}Putative hexokinase-2F6Y855nucleotide binding; catalytic activitycytoplasm; membrane; mitochondrionmetabolic process3.26E−041.2491Ribosomal protein L37F7FYI2RNA binding; structural molecule activity; metal ion bindingcytoplasm; ribosome; cytosolmetabolic process3.51E−031.2492Pyruvate kinaseF7FI39metal ion binding; catalytic activity--metabolic process1.07E−021.2493Protein phosphatase 1B isoform 2H9EM08metal ion binding; catalytic activity--metabolic process1.40E−021.2494[a](#tblfn0005){ref-type="table-fn"}Glycogen synthase kinase-3 alphaG7PXQ8nucleotide binding; catalytic activitymembranemetabolic process4.34E−031.2495Phosphoserine aminotransferaseF7H2J8catalytic activity--metabolic process1.01E−031.2596Histone H2AH9FCA2DNA binding; protein bindingchromosome; nucleus; membranecell organization and biogenesis; metabolic process2.02E−031.2597EF-hand domain-containing protein D2H9FC53metal ion binding----6.88E−041.2598[a](#tblfn0005){ref-type="table-fn"}Putative ATP-dependent RNA helicase DDX10F7BIN5nucleotide binding; catalytic activity----1.20E−041.2599[a](#tblfn0005){ref-type="table-fn"}Putative pterin-4-alpha-carbinolamine dehydrataseF7F694catalytic activity; protein bindingnucleus; cytoplasmmetabolic process; cell organization and biogenesis1.85E−021.26100Integrin beta 3F7FG54receptor activity; protein bindingmembrane; cell surfacecell organization and biogenesis; cell communication; regulation of biological process; response to stimulus; development; cellular component movement; cell proliferation; coagulation2.60E−041.26101Similar to human exocyst complex component 7I7GLB8--cytoplasmtransport5.30E−031.27102[a](#tblfn0005){ref-type="table-fn"}Putative leucine-rich repeat flightless-interacting protein 1F6S3D2------1.48E−031.27103[a](#tblfn0005){ref-type="table-fn"}Uncharacterized proteinG7P460------8.80E−041.28104Eukaryotic initiation factor 4A-I isoform 1H9FAB5nucleotide binding; RNA binding; catalytic activitycytoplasmmetabolic process2.51E−031.29105[a](#tblfn0005){ref-type="table-fn"}Phosphatidylinositol transfer protein beta isoform isoform 2F7G7C8----transport1.70E−021.29106Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 2G7NE91protein binding--metabolic process4.14E−031.30107[a](#tblfn0005){ref-type="table-fn"}Putative tripartite motif-containing protein 47 (TRIM47)F7HF49protein binding; metal ion bindingintracellular--2.65E−021.31108UDP-N-acetylhexosamine pyrophosphorylaseF7CXU2catalytic activity--metabolic process3.83E−021.32109[a](#tblfn0005){ref-type="table-fn"}Putative protein EGK_20713F7B9G5protein binding----3.42E−031.32110[a](#tblfn0005){ref-type="table-fn"}Putative 60S ribosomal protein L23a-likeF7HD49nucleotide binding; structural molecule activitycytoplasm; ribosomemetabolic process3.89E−041.33111Mitochondrial import inner membrane translocase subunit Tim13F6R7Z6metal ion bindingcytoplasm; mitochondrioncell organization and biogenesis; transport1.98E−041.33112Poly \[ADP-ribose\] polymerase 9 isoform cH9ZE68catalytic activitymembrane--3.46E−031.34113[a](#tblfn0005){ref-type="table-fn"}Serpin B6F7BRQ5enzyme regulator activityextracellular--7.69E−041.35114EH domain-containing protein 4F7HAE5catalytic activity; metal ion binding; protein binding; nucleotide bindingcytoplasm; endoplasmic reticulum; endosome; membranemetabolic process; transport; cell organization and biogenesis2.73E−041.35115Calponin-like integrin-linked kinase-binding proteinG7PQP7protein binding; catalytic activitymembranecell communication; regulation of biological process; response to stimulus; metabolic process5.57E−041.35116[a](#tblfn0005){ref-type="table-fn"}Putative protein EGK_00649G8F2R2transporter activitymembranetransport2.83E−031.36117Ribosomal RNA-processing protein 8F7C3H4catalytic activity; protein bindingnucleus; organelle lumen; cytoplasm; membrane; chromosomemetabolic process; regulation of biological process; cell communication; response to stimulus; cell death3.59E−031.36118Microtubule-associated protein 1BG7P7P5protein binding; catalytic activitycytoskeleton; membranecell organization and biogenesis3.37E−051.37119FMRP-interacting protein 2G7NGR9------3.95E−041.42120[a](#tblfn0005){ref-type="table-fn"}Putative centrosomal protein of 89 kDa isoform X1F7H5V4protein binding----8.26E−041.44121[a](#tblfn0005){ref-type="table-fn"}Ubiquitin-conjugating enzymeF6ULI1catalytic activity----3.58E−031.49122Nucleolar complex protein 14G7NVR8--membrane--4.14E−071.52123Ubiquitin-like protein ISG15F7GS84protein bindingextracellularmetabolic process; regulation of biological process; defense response; response to stimulus1.59E−051.76124[a](#tblfn0005){ref-type="table-fn"}Putative caspase-7 isoform X1G7PDZ9catalytic activitycytoplasmmetabolic process; cell death2.21E−041.76125[a](#tblfn0005){ref-type="table-fn"}Putative tRNA pseudouridine synthase Pus10H9FK14------2.56E−042.21126OCIA domain-containing protein 1 isoform 2H9FWA7--membrane--1.20E−022.50[^1][^2]

3.2. GO annotations of the DEPs {#sec0060}
-------------------------------

The Gene Ontology (GO) database has been widely used for describing protein function in a standardized format. According to their GOCs, the 126 DEPs were annotated as cellular component, biological process, or molecular function. The GO annotations are shown in [Table 2](#tbl0010){ref-type="table"}, and distributions of the GO annotations are shown in [Fig. 3](#fig0015){ref-type="fig"} . Seventy-eight DEPs were distributed among 16 groups of biological processes ([Fig. 3](#fig0015){ref-type="fig"}A). The metabolic process (GO:0008152), cellular process (GO:0009987), single-organism process (GO:0044699), and biological regulation (GO:0065007) groups contained the highest proportions of the biological process DEPs. There were more up-regulated proteins in the cellular component organization group (GO:0071840) than down-regulated proteins. Seventy-four DEPs were distributed among eight cellular component groups ([Fig. 3](#fig0015){ref-type="fig"}B), among which the organelle (GO:0043226) and cell (GO:0005623) groups contained the highest proportion of cellular component DEPs. There were more down-regulated DEPs in the membrane group (GO:0016020) than up-regulated DEPs, and there were more up-regulated DEPs in the macromolecular complex group (GO:0032991) than down-regulated DEPs. Ninety-seven DEPs were distributed among eight molecular function groups ([Fig. 3](#fig0015){ref-type="fig"}C), among which the binding (GO:0005488) and catalytic activity (GO:0003824) groups contained the greatest proportion of molecular function DEPs.Fig. 3The Gene Ontology (GO) categories of the differentially expressed proteins at level 2. (A) Biological process GO categories; (B) cellular component GO categories; (C) molecular function GO categories.

3.3. KEGG pathway analysis of the DEPs {#sec0065}
--------------------------------------

The kyoto encyclopedia of genes and genomes (KEGG) pathway is a collection of pathway maps that represent molecular interactions and reaction networks in cells. Seventy-five of the 126 DEPs identified were annotated, and mapped to a total of six KEGG pathway categories, which included the metabolism, organismal systems, cellular processes, genetic information processing, environmental information processing, and diseases pathway categories ([Fig. 4](#fig0020){ref-type="fig"} ). The annotations in the metabolism, organismal systems, and diseases pathway categories represented 32, 25, and 36 pathway groups, respectively ([Fig. 4](#fig0020){ref-type="fig"}A, B and F).Fig. 4Analysis of the KEGG pathway of the differentially expressed proteins. (A) Metabolism; (B) organismal systems; (C) cellular processes; (D) genetic information processing; (E) environmental information processing; (F) diseases.

The annotations in metabolism pathways category included the carbohydrate, energy, lipid, nucleotide, amino acid, glycan biosynthesis, cofactors and vitamins, biosynthesis of other secondary metabolites, and xenobiotics pathway groups ([Fig. 4](#fig0020){ref-type="fig"}A). The annotations in the organismal systems category included the Toll-like receptor (TLR) signaling (ko04620), RIG-I-like receptor (RLR) signaling (ko04622), and natural killer cell mediated cytotoxicity (ko04650) pathway groups ([Fig. 4](#fig0020){ref-type="fig"}B), which represent pathways related primarily to the immune response to virus infection. The largest number of DEPs in the cellular process category were mapped to the lysosome (ko04142) pathway group, all ten of which were down-regulated DEPs ([Fig. 4](#fig0020){ref-type="fig"}C). The annotations in the genetic information processing category included pathway groups related to DNA replication and repair, transcription, translation, and the folding, sorting, and degradation of proteins ([Fig. 4](#fig0020){ref-type="fig"}D). The annotations in the environmental information processing category included the PI3K-Akt signaling (ko04151), mitogen-activated protein kinase (MAPK) signaling (ko04010), Jak-STAT signaling (ko04630), TNF signaling (ko04668), and cell adhesion molecule (ko04514) pathway groups ([Fig. 4](#fig0020){ref-type="fig"}E), all of which represented signal transduction and signaling-molecule interactions that have been shown to be associated with virus infection. The annotations in the diseases category included the human T-cell leukemia virus infection, Epstein--Barr virus infection, hepatitis C, hepatitis B, and measles pathway groups ([Fig. 4](#fig0020){ref-type="fig"}F), all of which are associated with virus infection involving in three down-regulated proteins and one up-regulated protein. Overall, more disease pathway groups were assigned to a single down-regulated DEP than those assigned to up-regulated DEPs. The integrin (β2 and β3 subunits) protein was annotated to the largest number of pathway groups (28), which included the organismal systems, environmental information processing, cellular processes, and diseases categories.

3.4. Verification of differential expression {#sec0070}
--------------------------------------------

The β tubulin as loading control, three down-regulated DEPs cystatin-C, apolipoprotein E4 and centrin-2, two up-regulated DEPs integrin-β3 and protein S100-A2, were selected to verify differential expression between the PEDV-infected and mock-infected Vero E6 cells. The immunoblotting analysis showed that the ratios of these proteins between the PEDV-infected and mock-infected groups were consistent with those obtained using the quantitative proteomics analysis ([Fig. 5](#fig0025){ref-type="fig"} ).Fig. 5Verification of the selected differential expression proteins by western blot. (A) β tubulin; (B) Integrin β3; (C) Protein S100-A2; (D) Apolipoprotein E4; (E) Centrin-2; (F) Cystatin-C. The iTRAQ quantitative ratio "*V*/*C* ratio" is shown in Figure.

4. Discussion {#sec0075}
=============

In our study, PEDV infection significantly alters protein expression in Vero E6 cells. The differentially expressed proteins (DEPs) annotated to virus infection-associated signaling pathways, autophagy, and virus entry-associated proteins were analyzed further to assess their potential roles in PEDV infection. In mammals, the first line of defense against virus infection is the innate immune system. Early antiviral responses are initiated upon the recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs), resulting in the production of interferons for the innate immune response and the maturation of dendritic cells for establishing acquired immunity ([@bib0285]). The PRRs are grouped into the TLRs, RLRs, and nucleotide binding-oligomerization domain-like receptors. Our results showed that PEDV infection induced the DEPs that participated in six signaling pathways involved in viral infection, including the RLR, Rap1, PI3K-Akt, MAPK, Jak-STAT, and TLR signaling pathways.

The PEDV is an enteric virus that infects the intestinal epithelial cells (IEC) of swine, causing severe diarrhea. [@bib0080] reported the RIG-I signaling pathway plays an important role in antiviral innate immunity mechanisms in IECs. [@bib0210] reported the Rap1A signaling pathway was associated with secretory diarrhea. The Jak-STAT signaling pathway regulates the adaptive and innate mechanisms related to mucosal immunity ([@bib0075], [@bib0260]). Our results showed that DEPs induced by PEDV infection in Vero E6 cells involved in the RLR, Rap1, and Jak-STAT signaling pathways. It has been reported that the TLR, MAPK, and PI3K-Akt signaling pathways play roles in host cell responses to coronaviruses ([@bib0150], [@bib0155], [@bib0145]). Our results demonstrate that the recognition of viral PAMPs by PRRs may mediate antiviral signaling in PEDV-infected Vero E6 cells.

Integrins are cell surface α/β heterodimeric glycoproteins that contribute to a variety of cellular functions ([@bib0225]). Combinations of the various isotypes of the α and β subunits of integrins generate more than 20 different integrin proteins. Previous studies have shown that various integrin molecules are used as receptors for virus attachment ([@bib0225], [@bib0240]). In our current study, the expression of integrin-β2 and -β3 was down-regulated and up-regulated, respectively, in response to PEDV infection. The upregulation of integrin-β3 expression is consistent with that observed in response to dengue virus infection ([@bib0300]). Our pathway analysis revealed that both integrin-β2 and -β3 are involved in 28 pathways that contribute to organismal systems, environmental information processing, cellular processes, and diseases.

The integrin αvβ3 protein has been shown to serve as an entry receptor for various viruses ([@bib0055], [@bib0160], [@bib0035], [@bib0175], [@bib0265]), some of which bind the integrin through an RGD sequence in a viral structural protein to initiate infection ([@bib0225]). The S protein of PEDV is a glycoprotein peplomer on the viral surface that plays an important role in receptor-mediated binding and cell membrane fusion. In our study, the integrin recognized sequences of PEDV S protein was analyzed based on [@bib0205] report. The results indicated that four conserved integrin-recognized amino acid motifs (Asp-Gly-Glu, Lys-Gly-Glu, Arg-Leu-Asp, and Leu-Asp-Val) were found in the S proteins of various PEDV strains (data not shown). These data suggest that integrin proteins may act as an infection associated protein for the attachment and entry of PEDV.

Autophagy is an essential component of host defenses against viral infection ([@bib0045]). [@bib0130] reported that β-coronaviruses induced autophagy. In our study, more DEPs were mapped to the autophagy pathway group than any of the other pathway groups. Fifteen DEPs were mapped to the lysosome and phagosome pathways. Of the 15 proteins, 12 (80%) were down-regulated DEPs. Although the autophagy pathway plays an antiviral role in virus-infected cells, the autophagy machinery is exploited by certain viruses for viral evasion and propagation. Our results showed that PEDV infection induced the downregulation of the expression of many autophagy-associated proteins. Therefore, PEDV infection might inhibit autophagy in Vero E6 cells, thus facilitating virus replication. Previous studies have shown that the microtubule-associated protein 1B is a useful biomarker protein for autophagy ([@bib0045]). We found that the expression of MAP1B was up-regulated 1.37-fold in the PEDV-infected Vero E6 cells. These results suggest that the PEDV induces autophagy.

Cystatin-C has been shown to reduce the replication of certain viruses, including the poliovirus, rhinovirus, and human coronaviruses OC43 and 229E ([@bib0115], [@bib0040]). The cleavage of S protein has been shown to be essential for the induction of cell-to-cell fusion and coronavirus entry into cells ([@bib0230]). [@bib0215] reported the transmembrane type II serine protease 2 enhanced infection of PEDV in Vero cells by increasing virus release. In our study, the reduced expression of cystatin-C might facilitate PEDV replication and release through the activation of cysteine-associated proteases in Vero E6 cells. Apolipoprotein E4, galectin, clusterin, and transferrin receptor 1 have also been shown to be associated with virus infection ([@bib0085], [@bib0180], [@bib0140], [@bib0250]), and may therefore function as infection-associated proteins in PEDV-infected Vero E6 cells. Additionally, the decreased in vitro expression of the adherens junction protein, such as cadherin, might be associated with a reduced integrity of PEDV-infected intestinal epithelial cells in vivo.

To the best of our knowledge, our study represents the analysis of the interactions between PEDV and Vero E6 cells using a quantitative proteomics technique. PEDV infection-associated pathways and proteins are described and discussed based on the bioinformatics analysis of the differentially expressed proteins. Our analysis of Vero E6 cell responses to PEDV infection identified relevant targets for subsequent in-depth studies of PEDV pathogenesis, expand the current knowledge base regarding the interaction between the PEDV and the host cell, and provide useful basic information about other coronaviruses. Although the Vero E6 cells are highly susceptible to PEDV infection and facilitate experimental design and performance for proteomics, the Vero E6 cell line is an interferon-deficient cell line and not a pig cell line. So, the detailed functions of these pathways and proteins in PEDV infection require further verification in the actual host cells of PEDV.
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[^1]: The names of the uncharacterized/putative proteins were annotated again and corrected by the blastp search in GenBank database of NCBI based on the primary identified protein sequences from the UniProtKB.

[^2]: The average *V*/*C* ratio \>1 represents the up-regulated proteins; the average *V*/*C* ratio \<1 represents the down-regulated proteins.
